Readership
Advanced Practice Nurses, Bioengineers, Biomedical Engineers/Technologists, Biomedical Researchers, Cardiologists, Cardiovascular Surgeons, Clinical Pharmacologists, Clinicians, Electrophysiologists, HyperTension Specialists, Internists, Interventionalists, Molecular Biologists, Nuclear Medicine Physicians, Pharmaco-Epidemiologists, Pharmacologists, Physicians, Physicians - Medicine, Physiologists, Policy Makers, Primary Care Physicians, Researchers, Vascular Medicine Specialists
Scope
The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, English language, peer-reviewed journal with a specific focus on clinical cardiovascular pharmacology. It publishes original articles concerning clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews. The journal aims to improve the pharmacological treatment of patients with cardiovascular disease through interpreting and integrating new scientific developments within this area.
While the focus is on clinical topics, basic research articles from fields such as physiology and molecular biology which contribute to an understanding of cardiovascular drug therapy are also considered, such as articles relevant to new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects.
EHJ-CVP is an official journal of the European Society of Cardiology (ESC) and the ESC Working Group on Cardiovascular Pharmacotherapy and is aimed at clinicians, physicians, researchers, and policy makers.
Sponsoring Association(s)
ESC Working Group on Cardiovascular Pharmacotherapy, European Society of Cardiology (ESC)